We investigated the effect of calibration with lyophilized calibrators on whole-blood glycohemoglobin (glyHb) results. One hundred three laboratories, using 20 different methods, determined glyHb in two lyophilized calibrators and two whole-blood samples. For whole-blood samples with low (5%) and high (9%) glyHb percentages, respectively, calibration decreased overall interlaboratory variation (CV) from 16% to 9% and from 11% to 6% and decreased intermethod variation from 14% to 6% and from 12% to 5%. Forty-seven laboratories, using 14 different methods, determined mean glyHb percentages in self-selected groups of 10 nondiabetic volunteers each. With calibration their overall mean (2SD) was 5.0% (0.5%), very close to the 5.0% (0.3%) derived from the reference method used in the Diabetes Control and Complications Trial. In both experiments the Abbott lMx and Vision showed deviating results. We conclude that, irrespective of the analytical method used, calibration enables standardization of glyHb results, reference values, and interpretation criteria. In the present study we investigated the effect of lyophilized calibrators on whole-blood glyHb results. First, in the "fresh sample comparison," we studied the effect of calibration on overall interlaboratory and intermethod variation and on the variation per method. This comparison involved 103 laboratories using 20 different methods to determine glyHb in two lyophilized calibrators, two lyophilized samples, and two wholeblood samples (one each with low and high glyHb content). In the second experiment, denoted as "biocheck," we examined the effect of calibration on the mean glyHb reference value and its interlaboratory variation. For this, 47 laboratories, using 14 different methods, additionally measured glyHb in 10 self-selected nondiabetic volunteers.
with low (5%) and high (9%) glyHb percentages, respectively, calibration decreased overall interlaboratory variation (CV) from 16% to 9% and from 11% to 6% and decreased intermethod variation from 14% to 6% and from 12% to 5%. Forty-seven laboratories, using 14 different methods, determined mean glyHb percentages in self-selected groups of 10 nondiabetic volunteers each. With calibration their overall mean (2SD) was 5.0% (0.5%), very close to the 5.0% (0.3%) derived from the reference method used in the Diabetes Control and Complications Trial. In both experiments the Abbott lMx and Vision showed deviating results. We conclude that, irrespective of the analytical method used, calibration enables standardization of glyHb results, reference values, and interpretation criteria. Lack of standardization is the major explanation for this phenomenon and solving this problem has become a major priority of the National Diabetes Data Group in the US (3). Recently, the group of Goldstein and Little (4-6) advocated a pragmatic approach for standardiza-
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tion: Hemolysates with assigned HbA1 values, based on careful examination
by an arbitrarily chosen HPLC method, were to be used as calibrators and, regardless of the measured glyHb type, results of all methods were to be corrected.
In our previous work we described the beneficial effect of this approach in 111 laboratories using 21 different methods (7) . The major limitation of that study was that it reperted the effect of lyophilized In the present study we investigated the effect of lyophilized calibrators on whole-blood glyHb results. First, in the "fresh sample comparison," we studied the effect of calibration on overall interlaboratory and intermethod variation and on the variation per method. This comparison involved 103 laboratories using 20 different methods to determine glyHb in two lyophilized calibrators, two lyophilized samples, and two wholeblood samples (one each with low and high glyHb content). In the second experiment, denoted as "biocheck," we examined the effect of calibration on the mean glyHb reference value and its interlaboratory variation. For this, 47 laboratories, using 14 different methods, additionally measured glyHb in 10 self-selected nondiabetic volunteers. 
MaterIals and Methods Study Design
Results
During the study it became apparent that lyophilized samples were not compatible with the glyHb assays of Abbott IMx and Vision. Additional studies, not reported here, showed that lyophilization raised the measured glyHb by 1-1.5% over the original whole-blood samples.
Therefore, data from both Abbott methods were not used for further evaluation.
The Bio-Rad chromatograms of whole-blood samples showed a small extra peak between HbA0 and HbA1C, probably due to denaturation during storage and transport. This artifact altered integration parameters, which yielded lower HbA1C percentages.
Because the quantitative effect was relatively small (0.3-0.4%) in the group of Diamat users in The Netherlands, these data were not rejected. The larger deviation observed by the Australian laboratory (-0.8%) was probably due to longer transport delay, and these data were not used in the calculations.
Fresh sample comparison. Table 1 shows the overall interlaboratory variation in lyophilized and whole-blood samples as derived from the present 1994 external quality-assurance survey (EQAS). Results with and without calibration for samples with low (5% HbA1) and high (9% HbA,) glyHb contents were compared with results from lyophilized samples in the previously published 1993 EQAS (7), which contained low (5% HbA1) and very high (14% HbA,) glyHb percentages. The calculation of the 1993 EQAS results included the Abbott data; therefore, to allow fair comparison, we recalculated the 1993 data with the Abbott data omitted. For samples with low glyHb, this calibration decreased the overall interlaboratory CV from 18% to 8% and from 16% to 9% in the lyophilized and whole-blood samples, respectively. In the samples with high glyHb, the decrease in CV was from 12% to 6% in the lyophffized sample and from 11% to 6% in whole blood. Samples with different glyHb values gave comparable overall interlaboratory SDs after calibration: 0.4%, 0.5%, and 0.6% (absolute Table 3 for method codes and for low and high glyHb contents. HbA1C percentages) at the low, high, and very high levels, respectively. Table 2 shows intermethod variation, without and with calibration, in lyophilized and whole-blood samples. Calibration produced a distinct decrease in CV for all samples. At low glyHb, the CV decreased from 17% to 4% in the lyophilized sample and from 14% to 6% in whole blood. At high glyllb, the decrease was from 12% to 4% and from 12% to 5%, respectively. Table 3 shows mean glyHb percentages without and with calibration of whole-blood samples for the various methods, as well as the interlaboratory
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SD per method.
Calibration reduced the glyHb percentages measured by Abbott IMx and Vision, especially in the high-glyHb samples.
Table 2. Intermethod variation, without and with calibration with lyophllized calIbrators, in whole blood
and lyophilized samples as determined in external quality assurance surveys at three glyHb contents.
Low glyHb
Lyophilized sample 19930
Lyophilizedsample 1993C Lyophilizedsample 1994" Whole-bloodsample 1994"
High glyHb
Lyophilized sample 1g94d
Whole-blood sample1994"
Ver/ highglyHb
Lyophilized sample 19930
Lyophilized sample 1993C
Footnotes as in Table 1 .
CV, % (and SD, %)
Wfthout With calibration calibration 
Immunochemica!methods
Dako(X) 3 Bayer(W) 2
Boehnnger (Y) 7
a GlyHb contents determined in whole blood prior to distribution with BloRad Diamat, calibrated with SKZL calibrators. #{176}Data for Abbott iMx and Vision were excluded from the calculation of overall mean, SD, and CV. ing electrophoresis (S) being at the upper limit and those by Beckman electrophoresis (R) at the lower limit.
With calibration the results of the various methods tended to cluster, except for those by Abbott Vision (E) and IMx (F) and possibly those by Sebia (T).
Biocheck. Fig. 2 shows the mean glyHb percentages in 47 independent cohorts of 10 nondiabetic volunteers, without and with use of calibrators.
Without calibration, the 47 laboratories measured a mean glyHb of 4.5% (SD 0.6%; median 4.6%). The mean SD per laboratory, as observed in 10 volunteers, amounted to 0.4%. With calibration, the mean glyHb was 5.0% (SD 0.2%; median 4.9%) and the mean SD per laboratory in 10 volunteers was 0.4%. The use of calibrators decreased the dispersion of results and yielded a mean glyHb percentage for nondiabetics near the expected 5% value.
Discussion
Previously, we showed that calibration with lyophili.zed calibrators (7) is a powerful means to standardize results of various glyHb methods. The limitation of that study was that it described the effect of lyophilized calibrators on lyophilized samples. In the present work we studied whether standardization with lyophiized calibrators was also achievable for whole-blood samples.
With respect to glyHb, the term "fresh sample comparison" was first used by Goldstein and Little (4) which had an overall mean of 5.0%, were equal to the mean glyHb used in the DCCT study for nondiabetic subjects. The distribution curves were not quite gaussian, but the median values were close to the means. The glyHb biological variation of a nondiabetic population amounts to 0.5% (11) , which implies that 95% of the assay results will be within 5.0% ± 1.0%. The mean for a ran- (14) , and Kolatkar et al., using intensive diabetes management, proposed a maximum allowable error of 1.2-2.1% (15) .
In conclusion, the present data show that glyHb results obtained from assays in whole-blood samples can effectively be standardized with iyophilized calibrators. Standardization of glyHb results and use of standardized interpretation criteria are strongly recommended.
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